Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

“[EGFR]-targeted drugs emerged, and we saw activity in patients with lung cancer. It wasn’t known for approximately 4 to 6 years later that there were mutations that caused that, but we had a breakthrough, and then we built on that.”

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine, discusses advances in EGFR inhibition throughout the past several decades for patients with lung cancer.